The role of colchicine in the prevention of cerebrovascular ischemia

Georgios Tsivgoulis, Aristeidis H. Katsanos, Georgios Giannopoulos, Vasiliki Panagopoulou, Dalius Jatuzis, Robin Lemmens, Spyridon Deftereos, Peter J. Kelly

Research output: Contribution to journalReview article

4 Citations (Scopus)

Abstract

Introduction: Despite the proven efficacy of anti-thrombotic, lipid-lowering, anti-hypertensive therapies and lifestyle modification changes for secondary ischemic stroke prevention, the risk of recurrent stroke, coronary events and vascular death remains substantial even for patients treated with high rates of established secondary preventive medications. Methods: In the present review, we summarize available literature data on the association between systemic inflammation and symptomatic atherosclerosis including recurrent cerebral ischemia. We also highlight the potential role of colchicine in the suppression of atherosclerosis-induced inflammation, plaque stabilization and thromboembolism prevention. Results: Accumulating evidence suggests that inflammation is of key importance in the pathophysiology of atherosclerotic plaque de-stabilization and thromboembolism, with inflammatory cells being involved in all stages of atherosclerosis development. Therefore, anti-inflammatory therapies targeting the atherosclerotic plaque inflammation may be important contributors in plaque stabilization and in the prevention of thromboembolic events. Colchicine is known to have multiple anti-inflammatory properties including inhibition of microtubule polymerization, leading to reduced secretion in monocyte-macrophages. Currently the randomized controlled CONVINCE trial is enrolling stroke patients to evaluate the effect of a daily low-dose of colchicine in reducing the rate of recurrent stroke and major vascular events. Conclusion: Inflammatory pathways seem to be key mediators in the development of atherosclerotic process, atheromatous plaque destabilization and thromboembolism. Colchicine as a novel therapeutic agent could be a safe and effective inhibitor of the inflammation cascade in patients with extra-or intracranial atherosclerosis or arteriolosclerosis, resulting in reduced vascular events.

Original languageEnglish (US)
Pages (from-to)668-674
Number of pages7
JournalCurrent Pharmaceutical Design
Volume24
Issue number6
DOIs
StatePublished - Jan 1 2018

Fingerprint

Colchicine
Ischemia
Inflammation
Thromboembolism
Atherosclerotic Plaques
Stroke
Blood Vessels
Atherosclerosis
Arteriolosclerosis
Anti-Inflammatory Agents
Intracranial Arteriosclerosis
Brain Ischemia
Microtubules
Polymerization
Antihypertensive Agents
Life Style
Monocytes
Therapeutics
Randomized Controlled Trials
Macrophages

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Drug Discovery

Cite this

Tsivgoulis, G., Katsanos, A. H., Giannopoulos, G., Panagopoulou, V., Jatuzis, D., Lemmens, R., ... Kelly, P. J. (2018). The role of colchicine in the prevention of cerebrovascular ischemia. Current Pharmaceutical Design, 24(6), 668-674. https://doi.org/10.2174/1381612824666180116100310

The role of colchicine in the prevention of cerebrovascular ischemia. / Tsivgoulis, Georgios; Katsanos, Aristeidis H.; Giannopoulos, Georgios; Panagopoulou, Vasiliki; Jatuzis, Dalius; Lemmens, Robin; Deftereos, Spyridon; Kelly, Peter J.

In: Current Pharmaceutical Design, Vol. 24, No. 6, 01.01.2018, p. 668-674.

Research output: Contribution to journalReview article

Tsivgoulis, G, Katsanos, AH, Giannopoulos, G, Panagopoulou, V, Jatuzis, D, Lemmens, R, Deftereos, S & Kelly, PJ 2018, 'The role of colchicine in the prevention of cerebrovascular ischemia', Current Pharmaceutical Design, vol. 24, no. 6, pp. 668-674. https://doi.org/10.2174/1381612824666180116100310
Tsivgoulis, Georgios ; Katsanos, Aristeidis H. ; Giannopoulos, Georgios ; Panagopoulou, Vasiliki ; Jatuzis, Dalius ; Lemmens, Robin ; Deftereos, Spyridon ; Kelly, Peter J. / The role of colchicine in the prevention of cerebrovascular ischemia. In: Current Pharmaceutical Design. 2018 ; Vol. 24, No. 6. pp. 668-674.
@article{4fab697261c441a7bb5fd6946e041bd6,
title = "The role of colchicine in the prevention of cerebrovascular ischemia",
abstract = "Introduction: Despite the proven efficacy of anti-thrombotic, lipid-lowering, anti-hypertensive therapies and lifestyle modification changes for secondary ischemic stroke prevention, the risk of recurrent stroke, coronary events and vascular death remains substantial even for patients treated with high rates of established secondary preventive medications. Methods: In the present review, we summarize available literature data on the association between systemic inflammation and symptomatic atherosclerosis including recurrent cerebral ischemia. We also highlight the potential role of colchicine in the suppression of atherosclerosis-induced inflammation, plaque stabilization and thromboembolism prevention. Results: Accumulating evidence suggests that inflammation is of key importance in the pathophysiology of atherosclerotic plaque de-stabilization and thromboembolism, with inflammatory cells being involved in all stages of atherosclerosis development. Therefore, anti-inflammatory therapies targeting the atherosclerotic plaque inflammation may be important contributors in plaque stabilization and in the prevention of thromboembolic events. Colchicine is known to have multiple anti-inflammatory properties including inhibition of microtubule polymerization, leading to reduced secretion in monocyte-macrophages. Currently the randomized controlled CONVINCE trial is enrolling stroke patients to evaluate the effect of a daily low-dose of colchicine in reducing the rate of recurrent stroke and major vascular events. Conclusion: Inflammatory pathways seem to be key mediators in the development of atherosclerotic process, atheromatous plaque destabilization and thromboembolism. Colchicine as a novel therapeutic agent could be a safe and effective inhibitor of the inflammation cascade in patients with extra-or intracranial atherosclerosis or arteriolosclerosis, resulting in reduced vascular events.",
author = "Georgios Tsivgoulis and Katsanos, {Aristeidis H.} and Georgios Giannopoulos and Vasiliki Panagopoulou and Dalius Jatuzis and Robin Lemmens and Spyridon Deftereos and Kelly, {Peter J.}",
year = "2018",
month = "1",
day = "1",
doi = "10.2174/1381612824666180116100310",
language = "English (US)",
volume = "24",
pages = "668--674",
journal = "Current Pharmaceutical Design",
issn = "1381-6128",
publisher = "Bentham Science Publishers B.V.",
number = "6",

}

TY - JOUR

T1 - The role of colchicine in the prevention of cerebrovascular ischemia

AU - Tsivgoulis, Georgios

AU - Katsanos, Aristeidis H.

AU - Giannopoulos, Georgios

AU - Panagopoulou, Vasiliki

AU - Jatuzis, Dalius

AU - Lemmens, Robin

AU - Deftereos, Spyridon

AU - Kelly, Peter J.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Introduction: Despite the proven efficacy of anti-thrombotic, lipid-lowering, anti-hypertensive therapies and lifestyle modification changes for secondary ischemic stroke prevention, the risk of recurrent stroke, coronary events and vascular death remains substantial even for patients treated with high rates of established secondary preventive medications. Methods: In the present review, we summarize available literature data on the association between systemic inflammation and symptomatic atherosclerosis including recurrent cerebral ischemia. We also highlight the potential role of colchicine in the suppression of atherosclerosis-induced inflammation, plaque stabilization and thromboembolism prevention. Results: Accumulating evidence suggests that inflammation is of key importance in the pathophysiology of atherosclerotic plaque de-stabilization and thromboembolism, with inflammatory cells being involved in all stages of atherosclerosis development. Therefore, anti-inflammatory therapies targeting the atherosclerotic plaque inflammation may be important contributors in plaque stabilization and in the prevention of thromboembolic events. Colchicine is known to have multiple anti-inflammatory properties including inhibition of microtubule polymerization, leading to reduced secretion in monocyte-macrophages. Currently the randomized controlled CONVINCE trial is enrolling stroke patients to evaluate the effect of a daily low-dose of colchicine in reducing the rate of recurrent stroke and major vascular events. Conclusion: Inflammatory pathways seem to be key mediators in the development of atherosclerotic process, atheromatous plaque destabilization and thromboembolism. Colchicine as a novel therapeutic agent could be a safe and effective inhibitor of the inflammation cascade in patients with extra-or intracranial atherosclerosis or arteriolosclerosis, resulting in reduced vascular events.

AB - Introduction: Despite the proven efficacy of anti-thrombotic, lipid-lowering, anti-hypertensive therapies and lifestyle modification changes for secondary ischemic stroke prevention, the risk of recurrent stroke, coronary events and vascular death remains substantial even for patients treated with high rates of established secondary preventive medications. Methods: In the present review, we summarize available literature data on the association between systemic inflammation and symptomatic atherosclerosis including recurrent cerebral ischemia. We also highlight the potential role of colchicine in the suppression of atherosclerosis-induced inflammation, plaque stabilization and thromboembolism prevention. Results: Accumulating evidence suggests that inflammation is of key importance in the pathophysiology of atherosclerotic plaque de-stabilization and thromboembolism, with inflammatory cells being involved in all stages of atherosclerosis development. Therefore, anti-inflammatory therapies targeting the atherosclerotic plaque inflammation may be important contributors in plaque stabilization and in the prevention of thromboembolic events. Colchicine is known to have multiple anti-inflammatory properties including inhibition of microtubule polymerization, leading to reduced secretion in monocyte-macrophages. Currently the randomized controlled CONVINCE trial is enrolling stroke patients to evaluate the effect of a daily low-dose of colchicine in reducing the rate of recurrent stroke and major vascular events. Conclusion: Inflammatory pathways seem to be key mediators in the development of atherosclerotic process, atheromatous plaque destabilization and thromboembolism. Colchicine as a novel therapeutic agent could be a safe and effective inhibitor of the inflammation cascade in patients with extra-or intracranial atherosclerosis or arteriolosclerosis, resulting in reduced vascular events.

UR - http://www.scopus.com/inward/record.url?scp=85047929558&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047929558&partnerID=8YFLogxK

U2 - 10.2174/1381612824666180116100310

DO - 10.2174/1381612824666180116100310

M3 - Review article

VL - 24

SP - 668

EP - 674

JO - Current Pharmaceutical Design

JF - Current Pharmaceutical Design

SN - 1381-6128

IS - 6

ER -